Technical Analysis for HOWL - Werewolf Therapeutics, Inc.

Grade Last Price % Change Price Change
B 18.48 -2.01% -0.38
HOWL closed down 2.01 percent on Wednesday, July 28, 2021, on 33 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical HOWL trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.01%
NR7 Range Contraction -2.01%
Inside Day Range Contraction -2.01%
Wide Bands Range Expansion -2.01%
180 Bullish Setup Bullish Swing Setup -4.99%
Inside Day Range Contraction -4.99%
Older End-of-Day Signals for HOWL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 16 hours ago
Down 2 % about 16 hours ago
Down 1% about 16 hours ago
Fell Below Previous Day's Low about 16 hours ago
Possible NR7 about 16 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Werewolf Therapeutics, Inc. Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors

Is HOWL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.99
52 Week Low 11.25
Average Volume 125,239
200-Day Moving Average 0.00
50-Day Moving Average 15.09
20-Day Moving Average 17.49
10-Day Moving Average 18.31
Average True Range 1.37
ADX 23.24
+DI 30.02
-DI 22.19
Chandelier Exit (Long, 3 ATRs) 17.49
Chandelier Exit (Short, 3 ATRs) 18.28
Upper Bollinger Bands 21.20
Lower Bollinger Band 13.78
Percent B (%b) 0.63
BandWidth 42.42
MACD Line 1.09
MACD Signal Line 0.98
MACD Histogram 0.1156
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.62
Resistance 3 (R3) 19.69 19.38 19.43
Resistance 2 (R2) 19.38 19.09 19.35 19.37
Resistance 1 (R1) 18.93 18.91 18.78 18.86 19.30
Pivot Point 18.62 18.62 18.54 18.59 18.62
Support 1 (S1) 18.17 18.33 18.02 18.10 17.66
Support 2 (S2) 17.86 18.15 17.83 17.59
Support 3 (S3) 17.41 17.86 17.53
Support 4 (S4) 17.34